Evonik Breaks Ground on New Lafayette Facility
Governor Eric J. Holcomb joined executives from Evonik, a global provider of drug delivery technologies, to expand the company’s production facility in Lafayette, creating more than 80 highly skilled, high-wage jobs by the end of 2025. With the expansion, the complex will be one of the largest sites for active pharmaceutical ingredients and Evonik's second-largest site in the U.S. employing 650 people.
Headquartered in Essen, Germany, Evonik is investing $220 million to expand its production facility at 1650 Lilly Road in Lafayette. The expansion will allow the rapid and flexible production of a variety of lipids that may serve future applications of mRNA technology in infectious disease control, cancer immunotherapy, protein replacement and gene therapy. The additional facility space also ensures a rapid and extensive supply of lipids to fuel the continuing battle against COVID-19.
“With this investment in lipid production, we are further expanding our leading position on the global market and specifically strengthening our Health Care business,” said Evonik CEO Christian Kullmann. “It supports our strategic transformation into ‘Next Generation Evonik’, contributing value-added solutions with superior environmental and socio-economic profiles to our customers.”
Active in more than 100 countries, Evonik employs 33,000 associates worldwide. Evonik’s Tippecanoe site in Lafayette is one of the world’s largest sites for active pharmaceutical ingredients and Evonik's second-largest site in the U.S. The company will begin hiring in Lafayette in 2024 for positions across operations, quality assurance and control, engineering and supply chain. Interested applicants may apply online.
